| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$9.2M | ROE | −317.65% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $84.6M | Trading Days | 610 |
| 52W High | 2.19 |
| 52W Low | 0.89 |
| % Off High | −43.84% |
| YTD | −7.52% | 1Y | −41.43% |
| Since incept. (ann.) | −43.44% |
| Ann. Volatility (1Y) | 77.85% | Ann. Volatility (3Y) | 130.99% |
| Sharpe (1Y) | −0.33 | Sharpe (3Y) | 0.13 |
| Max Drawdown (1Y) | −56.23% | Max Drawdown (3Y) | −92.28% |
| Beta (3Y, vs SPY) | −0.26 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| INO | INOVIO PHARMACEUTICALS, INC. | $84.7M | — |
| GNPX | Genprex, Inc. | $85.0M | — |
| RLYB | Rallybio Corp | $85.6M | — |
| LFVN | Lifevantage Corp | $81.1M | 8.6 |
| BMEA | Biomea Fusion, Inc. | $90.4M | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.8M | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $92.0M | — |
| VRCA | Verrica Pharmaceuticals Inc. | $92.8M | — |
| PLYX | Polaryx Therapeutics, Inc. | $92.8M | — |
| ACET | Adicet Bio, Inc. | $76.7M | — |
| COYA | Coya Therapeutics, Inc. | $93.8M |
| — |
| ONCY | ONCOLYTICS BIOTECH INC | $94.5M | — |
